High-sensitivity C-reactive protein : A useful marker for cardiovascular disease risk prediction and the metabolic syndromeRIFAI, Nader.Clinical chemistry (Baltimore, Md.). 2005, Vol 51, Num 3, pp 504-505, issn 0009-9147, 2 p.Article

High sensitivity immunoassays for C-reactive protein: Promises and pitfallsLEDUE, Thomas B; RIFAI, Nader.Clinical chemistry and laboratory medicine. 2001, Vol 39, Num 11, pp 1171-1176, issn 1434-6621Article

Population distributions of C-reactive protein in apparently healthy men and women in the United States: Implication for clinical interpretationRIFAI, Nader; RIDKER, Paul M.Clinical chemistry (Baltimore, Md.). 2003, Vol 49, Num 4, pp 666-669, issn 0009-9147, 4 p.Article

High-sensitivity C-reactive protein : A novel and promising marker of coronary heart diseaseRIFAI, Nader; RIDKER, Paul M.Clinical chemistry (Baltimore, Md.). 2001, Vol 47, Num 3, pp 403-411, issn 0009-9147Article

High-Sensitivity C-Reactive Protein and Cardiovascular DiseaseYOUNG, Ian; RIFAI, Nader.Clinical chemistry (Baltimore, Md.). 2009, Vol 55, Num 2, issn 0009-9147, 187 p.Serial Issue

Preanalytic and analytic sources of variations in C-reactive protein measurement: Implications for cardiovascular disease risk assessmentLEDUE, Thomas B; RIFAI, Nader.Clinical chemistry (Baltimore, Md.). 2003, Vol 49, Num 8, pp 1258-1271, issn 0009-9147, 14 p.Article

C-reactive protein and cardiovascular disease: a review of risk prediction and interventionsDE FERRANTI, Sarah; RIFAI, Nader.Clinica chimica acta. 2002, Vol 317, Num 1-2, pp 1-15, issn 0009-8981Article

Proposed cardiovascular risk assessment algorithm using high-sensitivity c-reactive protein and lipid screeningRIFAI, Nader; RIDKER, Paul M.Clinical chemistry (Baltimore, Md.). 2001, Vol 47, Num 1, pp 28-30, issn 0009-9147Article

Protein biomarker discovery and validation : the long and uncertain path to clinical utilityRIFAI, Nader; GILLETTE, Michael A; CARR, Steven A et al.Nature biotechnology. 2006, Vol 24, Num 8, pp 971-983, issn 1087-0156, 13 p.Article

Methods for measurement of LDL-cholesterol: A critical assessment of direct measurement by homogeneous assays versus calculationNAUCK, Matthias; WARNICK, G. Russell; RIFAI, Nader et al.Clinical chemistry (Baltimore, Md.). 2002, Vol 48, Num 2, pp 236-254, issn 0009-9147Article

Soluble intercellular adhesion molecule-1, soluble vascular adhesion molecule-1, and the development of symptomatic peripheral arterial disease in menPRADHAN, Aruna D; RIFAI, Nader; RIDKER, Paul M et al.Circulation (New York, N.Y.). 2002, Vol 106, Num 7, pp 820-825, issn 0009-7322Article

Evolution of methods for measurement of HDL-cholesterol : From ultracentrifugation to homogeneous assaysWARNICK, G. Russell; NAUCK, Matthias; RIFAI, Nader et al.Clinical chemistry (Baltimore, Md.). 2001, Vol 47, Num 9, pp 1579-1596, issn 0009-9147Article

C-Reactive Protein : Eighty Years from Discovery to Emergence as a Major Risk Marker for Cardiovascular DiseaseRIDKER, Paul M.Clinical chemistry (Baltimore, Md.). 2009, Vol 55, Num 2, pp 209-215, issn 0009-9147, 7 p.Article

Markers of the acute phase response in cardiovascular disease: An updateWHICHER, John; RIFAI, Nader; BIASUCCI, Luigi M et al.Clinical chemistry and laboratory medicine. 2001, Vol 39, Num 11, pp 1054-1064, issn 1434-6621Article

Interleukin-6 Receptor Gene, Plasma C-Reactive Protein, and Diabetes Risk in WomenLU QI; RIFAI, Nader; HU, Frank B et al.Diabetes (New York, NY). 2009, Vol 58, Num 1, pp 275-278, issn 0012-1797, 4 p.Article

Myocardial Infarction in a 72-Year-Old Woman with Low LDL-C and Increased hsCRP: Implications for Statin TherapyRIDKER, Paul M.Clinical chemistry (Baltimore, Md.). 2009, Vol 55, Num 2, pp 369-375, issn 0009-9147, 7 p.Article

Novel risk factors for systemic atherosclerosis : A comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial diseaseRIDKER, Paul M; STAMPFER, Meir J; RIFAI, Nader et al.JAMA, the journal of the American Medical Association. 2001, Vol 285, Num 19, pp 2481-2485, issn 0098-7484Article

Is hsCRP Back on Board? Implications from the JUPITER TrialKOENIG, Wolfgang.Clinical chemistry (Baltimore, Md.). 2009, Vol 55, Num 2, pp 216-218, issn 0009-9147, 3 p.Article

Interleukin-6 Receptor Gene Variations, Plasma Interleukin-6 Levels, and Type 2 Diabetes in U.S. WomenLU QI; RIFAI, Nader; HU, Frank B et al.Diabetes (New York, NY). 2007, Vol 56, Num 12, pp 3075-3081, issn 0012-1797, 7 p.Article

Simultaneous measurement of plasma ropivacaine and bupivacaine concentrations by HPLC with UV detectionRIFAI, Nader; HSIN, Olivia; HOPE, Todd et al.Therapeutic drug monitoring. 2001, Vol 23, Num 2, pp 182-186, issn 0163-4356Article

Soluble P-selectin and the risk of future cardiovascular eventsRIDKER, Paul M; BURING, Julie E; RIFAI, Nader et al.Circulation (New York, N.Y.). 2001, Vol 103, Num 4, pp 491-495, issn 0009-7322Article

Plasma fluorescent oxidation products as potential markers of oxidative stress for epidemiologic studiesTIANYING WU; WILLETT, Walter C; RIFAI, Nader et al.American journal of epidemiology. 2007, Vol 166, Num 5, pp 552-560, issn 0002-9262, 9 p.Article

No effect of β-carotene supplementation on risk of nonmelanoma skin cancer among men with low baseline plasma β-caroteneSCHAUMBERG, Debra A; FRIELING, Uta M; RIFAI, Nader et al.Cancer epidemiology, biomarkers & prevention. 2004, Vol 13, Num 6, pp 1079-1080, issn 1055-9965, 2 p.Article

The Evolving Role of C-Reactive Protein in AtherothrombosisDEVARAJ, Sridevi; SINGH, Uma; JIALAL, Ishwarlal et al.Clinical chemistry (Baltimore, Md.). 2009, Vol 55, Num 2, pp 229-238, issn 0009-9147, 10 p.Article

Fasting Compared With Nonfasting Lipids and Apolipoproteins for Predicting Incident Cardiovascular EventsMORA, Samia; RIFAI, Nader; BURING, Julie E et al.Circulation (New York, N.Y.). 2008, Vol 118, Num 10, pp 993-1001, issn 0009-7322, 9 p.Article